Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pathological Myopia
Conditions
Pathological Myopia
Trial Timeline
Oct 1, 2010 → Aug 1, 2012
NCT ID
NCT01217944About Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT
Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT is a phase 3 stage product being developed by Novartis for Pathological Myopia. The current trial status is completed. This product is registered under clinical trial identifier NCT01217944. Target conditions include Pathological Myopia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01217944 | Phase 3 | Completed |
Competing Products
4 competing products in Pathological Myopia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olanzapine + sugar pill | Eli Lilly | Phase 3 | 77 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 49 |
| Gadoversetamide | Guerbet | Approved | 77 |